Followers | 8 |
Posts | 744 |
Boards Moderated | 0 |
Alias Born | 07/16/2006 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 16, 2010 12:35:56 PM
Foolish, I'm not troubled by the possible sale of the pharmaceutical business... Albeit, I don't relish the idea of selling it for a substantial loss.
I've been uneasy with the thought that SRDX might morph into a low-margin high-volume business model such as that characterizing a contract manufacturer. I had been comforted by the thought that the initial costs might be recouped fairly rapidly by manufacture of a Lucentis long acting release formulation. However, my reading of the recent 10K is that the Lucentis program is essentially dead. see pg 3 of: http://www.sec.gov/Archives/edgar/data/924717/000095012310113522/c61767e10vk.htm
On October 5, 2009, we entered into a License and Development Agreement with F. Hoffmann-La Roche, Ltd. (“Roche”) and Genentech, Inc., a member of the Roche Group (“Genentech”). Under the terms of the License Agreement, Roche and Genentech have an exclusive license to develop and commercialize a sustained drug delivery formulation of Lucentis® (ranibizumab injection) utilizing SurModics’ proprietary biodegradable microparticle drug delivery system. Under the terms of the agreement, we received an upfront licensing fee of $3.5 million, are eligible to receive potential payments of up to approximately $200 million in fees and milestone payments in the event of the successful development and commercialization of multiple products, and will be paid for development work done on these products. Roche and Genentech will have the right to obtain manufacturing services from SurModics. In the event a commercial product is developed, we will also receive royalties on sales of such product. During fiscal 2010, the focus of our development activities have changed, primarily as a result of technical issues experienced in the Lucentis® microparticle product development program. Such technical issues reflect the inherent challenges often experienced in the development of new or reformulated pharmaceutical products. We are continuing to collaborate with Genentech under our agreement on sustained drug delivery products utilizing our proprietary biodegradable microparticle drug delivery system. However, the program remains subject to a number of risks and uncertainties, including those detailed under the heading “Risk Factors” in Item 1A of this Form 10-K.
Recent SRDX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:06:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:25:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:24:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:02:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 12:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:00:10 AM
- Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results • Business Wire • 07/31/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/09/2024 05:49:02 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 07/08/2024 08:28:06 PM
- Kuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law Firm • PR Newswire (US) • 06/17/2024 12:08:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/10/2024 08:57:37 PM
- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. • Business Wire • 06/10/2024 11:00:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc. • PR Newswire (US) • 05/29/2024 10:36:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 12:04:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 11:28:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 11:27:01 AM
- Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million • Business Wire • 05/29/2024 11:00:00 AM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/24/2024 08:01:05 PM
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance • Business Wire • 05/01/2024 11:00:00 AM
- Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 • Business Wire • 04/19/2024 11:00:00 AM
- Surmodics to Participate in Upcoming Investor Conferences in March and April • Business Wire • 02/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:22:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:16:12 PM
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM